CD274 and small cell lung carcinoma: For instance, pooled analysis of KEYNOTE-158 and KEYNOTE-028 trials revealed that pembrolizumab exhibited antitumor activity in heavily pretreated SCLC patients regardless of PD-L1 expression status (Chung et al., 2020).